S1933: A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status

S1933: A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status

The following study has recently been activated for patient enrollment by The University of Illinois Cancer Center Clinical Trials Office (CTO). Clink on the link to learn about the details regarding the study on clinicaltrials.gov.

For more information or questions about a study, email cancertrials@uic.edu or call 312-355-5112.

S1933: A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status

Sponsor: National Cancer Institute

Principal Investigator: Lawrence Feldman, MD

Leave a Reply